Abstract
The matrix metalloproteinases (MMPs) are well established as mediators of tumor invasion and metastasis. The classic view that these enzymes simply provide a mechanism for the breakdown of connective tissue barriers led to development of synthetic MMP inhibitors for cancer therapy. The lack of understanding of the complex roles of MMPs in cancer accounts for the failure of this strategy to significantly impact cancer therapy. It is now recognized that members of the MMP family function at all stages of cancer development to both promote and inhibit tumor progression. This overview summarizes recent evidence to support the emerging roles for MMP in all aspects of cancer progression, including tumor cell growth, programmed cell death, and tumor angiogenesis in addition to their classic role in cell invasion and metastasis. The MMP-dependent stimulation of tumor cell growth, stimulation of cell migration, and generation of cryptic sites and signals from within the extracellular matrix (ECM) are reviewed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100: 57–70.
Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295: 2387–92.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2: 161–74.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92: 827–39.
Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews. Cancer 2002, 2: 657–72.
Bode, W. Structural basis of matrix metalloproteinase function. Biochemical Society Symposia 2003, 1–14.
Crocker SJ, Pagenstecher A, Campbell LL. The TIMPs tango with MMPs and more in the central nervous system. J. Neurosci. Res. 2004, 75: 1–11.
Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 2000, 1477: 267–83.
Lambert E, et al. TIMPs as multifacial proteins. Critical Reviews in Oncology Hematology 2004, 49: 187–198.
Takahashi C, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. USA 1998, 95: 13221–6.
Oh J, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107: 789–800.
Hoegy SE, et al. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKRgrowth factor signaling independent of metalloproteinase inhibition. J. Biol. Chem. 2001, 276: 3203–14.
Seo DW, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114: 171–80.
Fedarko NS, et al. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB Journal 2004, 18: 734–6.
Liotta LA, et al. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc. Natl. Acad. Sci. USA 1979, 76: 2268–72.
Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64: 327–36.
Polette M, et al. Tumour invasion and matrix metalloproteinases. Critical Reviews in Oncology-Hematology 2004, 49: 179–86.
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annual Review of Cell & Developmental Biology 2001, 17: 463–516.
Toole BP, Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Current Topics in Developmental Biology 2003, 54: 371–89.
Monteagudo C, et al. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am. J. Pathol. 1990, 136: 585–92.
Gururajan R, et al. Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome Research 1998, 8: 929–39.
Gururajan R, et al. Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics 1998, 52: 101–6.
Llano E, et al. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res. 1999, 59: 2570–6.
Rutter JL, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998, 58: 5321–5.
Tower GB, et al. Erk 1/2 differentially regulates the expression from the 1G/2G single nucleotide polymorphism in the MMP-1 promoter in melanoma cells. Biochimica et Biophysica Acta 2002, 1586: 265–74.
Tower GB, Coon CI, Brinckerhoff CE. The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells. Breast Cancer Res. Treat. 2003, 82: 75–82.
Tower GB, et al. Fra-1 targets the AP-1 site/2G single nucleotide polymorphism (ETS site) in the MMP-1 promoter. Eur. J. Biochem. 2003, 270: 4216–25.
Martignetti JA, et al. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat. Genet. 2001, 28: 261–5.
Zhou Y, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 2004, 25: 399–404.
Sternlicht MD, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98: 137–46.
Sternlicht MD, Bissell MJ, Werb Z. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene 2000, 19: 1102–13.
Wilson CL, et al. Intertinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA 1997, 94: 1402–1407.
Crawford HC, et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999, 18: 2883–2891.
George SJ, Dwivedi A. MMPs, Cadherins, and Cell Proliferation. Trends in Cardiovascular Medicine 2004, 14: 100–105.
Noe V, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Science 2001, 114: 111–118.
Bergers G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2000, 2: 737–744.
Whitelock JM, et al. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271: 10079–10086.
Manes S, et al. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J. Biol. Chem. 1999, 274: 6935–45.
Manes S, et al. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J. Biol. Chem. 1997, 272: 25706–12.
Mu D, et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J. Cell Biol. 2002, 157: 493–507.
Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes. Dev. 1999, 13: 35–48.
Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes & Development 2000, 14: 163–76.
Dallas SL, et al. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 2002, 277: 21352–60.
Lauffenburger DA, Horowitz AF. Cell Migration: A Physically Integrated Molecular Process. Cell 1996, 84: 359–369.
Gumbiner BM. Cell Adhesion: The Molecular Basis of Tissue Architecture and Morphogenesis. Cell 1996, 84: 345–357.
Mitchison TJ, Cramer LP. Actin-Base Cell Motility and Cell Locomotion. Cell 1996, 84: 371–379.
Tapon N, Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr. Opin. Cell Biol. 1997, 9: 86–92.
Felsenfeld DP, et al. Selective regulation of integrin—cytoskeleton interactions by the tyrosine kinase Src. Nat. Cell Biol. 1999, 1: 200–6.
Choquet D, Felsenfeld DP, Sheetz MP. Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. Cell 1997, 88: 39–48.
Sheetz MP, Felsenfeld DP, Galbraith CG. Cell migration: regulation of force on extracellular-matrix-integrin complexes. Trends Cell Biol. 1998, 8: 51–4.
Brooks PC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85: 683–693.
Brooks PC, et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998, 92: 391–400.
Itoh T, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998, 58: 1048–1051.
Wolf K, et al. Compensation mechanism in tumor cell migration: mesenchymalamoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160: 267–77.
Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Reviews. Cancer 2003, 3: 362–74.
Hiraoka N, et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998, 95: 365–377.
Hotary KB, et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and-independent processes. Journal of Experimental Medicine 2002, 195: 295–308.
Hotary KB, et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003, 114: 33–45.
Sabeh F, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. 2004, 167: 769–781.
Giannelli G, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277: 225–8.
Hangai M, et al. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol. 2002, 161: 1429–37.
Xu J, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 2001, 154: 1069–79.
O’Reilly MS, et al. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. Biol. Chem. 1999, 274: 29568–71.
Dong ZY, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997, 88: 801–810.
Cornelius LA, et al. Matrix metalloproteinases generate angiostatin: Effects on neovascularization. Journal of Immunology 1998, 161: 6845–6852.
Hamano Y, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha 3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alpha V beta 3 integrin. Cancer Cell 2003, 3: 589–601.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer
About this chapter
Cite this chapter
Stetler-Stevenson, W.G., Seo, DW. (2006). Matrix Metalloproteinases in Tumor Progression. In: Wells, A. (eds) Cell Motility in Cancer Invasion and Metastasis. Cancer Metastasis - Biology and Treatment, vol 8. Springer, Dordrecht. https://doi.org/10.1007/1-4020-4009-1_7
Download citation
DOI: https://doi.org/10.1007/1-4020-4009-1_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-4008-5
Online ISBN: 978-1-4020-4009-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)